Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
about
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacyValganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection.Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran.Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxisPulmonary complications of solid organ and hematopoietic stem cell transplantation.Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Cytomegalovirus infection in renal transplant recipients.Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.Successful embolization of a cytomegalovirus-related duodenal ulcer in a kidney-pancreas transplant recipient.Cytomegalovirus esophagitis presents as chest pain in a renal transplant recipient.Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis.Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients.Cellular immune responses to cytomegalovirus in renal transplant recipients.Lack of cytomegalovirus transmission after pancreatic islet transplantation.Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation
P2860
Q28475480-546959B7-96D6-4E3E-8D1C-146C1B234D20Q33363887-F98CD27F-D0C6-4DCF-9CDD-DB9323D5FC83Q33364367-5A33759B-ACD7-487E-BBFD-38CB2D6E7E84Q33374318-38D5551C-DCCE-4811-93EB-6F4CD0D5FB54Q33522300-5578E614-3249-4BC9-AA0C-28062D80A7ADQ33561715-DD5B4126-5209-4B29-93ED-941765A78136Q33624126-BE78D12D-C438-4329-BD18-03312F03685FQ34065300-E52E40F0-2532-4543-BD59-667EE5EEC871Q35140692-F91208F3-A61C-4C9E-8714-6CAA701327B7Q35740698-9AE2DA84-F37F-4AD7-99AE-1E81154166CBQ35917319-AE982528-E951-44E5-A564-FE92B5EE0E00Q36043642-4A427A68-227C-4B6F-B3B3-58CF1821E7B3Q36868806-1536C383-E9C8-4A3D-9C5E-8001F82486FDQ37013588-34A28D8D-5B57-4295-9A64-907FEF668767Q37065216-E79CD7D8-28D0-42E7-AC18-6758F923248AQ37680941-89B47C50-14F7-48C5-A380-A40FD8D9834CQ38034186-B42FAB60-0B5B-49A9-9536-57D20CEFC527Q38364698-4EC09D46-C1C3-419F-80EA-AAB4666D06FEQ40464141-E3222F21-46B6-4770-B96A-F4BD16A099EBQ40537018-C6CA5B65-57BA-48DE-8B5C-8234060387FAQ40611482-D3BDBD5D-6F2B-47B4-AB61-ADFBAAECCB9BQ41128262-F743DCC8-C140-4A1E-9709-1493A915E996Q41496012-1B95EF62-EB15-4E8E-B03F-AFF9DCDFF0DAQ42260511-BC86CE40-3473-4691-A018-8DE1DE503EDBQ42272736-1CD19B2A-34AB-49E2-ADA4-E6B9C2E4DB10Q43090723-E66EBB9B-0AB1-48B2-992B-3CB82AD2EE43Q44079966-615A8462-5B1A-4FA7-A410-01140CB73603Q44695065-F217A4DB-37B1-4AAE-8B2C-C43237AE7908Q44963384-37280E52-3EF2-4A13-BE90-5E22043A3703Q45214565-4E8ECB14-009A-4BE9-AB34-4D05C6E80CCBQ45250680-BB9EBE9B-9D1E-4B44-B807-8F66F6CCA557Q45289899-29ADDD67-569C-4FB5-9FDD-0D50198DBD7BQ46764122-D5E68BDD-B89C-41E6-B4D1-7E13EEED2C54Q58998329-D45527F7-7684-4CD7-BEF9-7D04D6AB12F8
P2860
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@en
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@nl
type
label
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@en
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@nl
prefLabel
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@en
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis.
@nl
P2093
P2860
P1476
Cytomegalovirus disease in hig ...... or valganciclovir prophylaxis
@en
P2093
Enver Akalin
Jonathan S Bromberg
Murphy Barbara
Sabera Hossain
Vinita Sehgal
P2860
P304
P356
10.1034/J.1600-6143.2003.00140.X
P407
P50
P577
2003-06-01T00:00:00Z